Immunology/Inflammation
Read More about this categoryShow Less
The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.
Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].
BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].
Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.
Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].
References
[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.
[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.
[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.
[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.
[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.
[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.
[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.
[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.
Research Areas
- 5-Lipoxygenase(17)
- Apoptosis(824)
- Cyclic GMP-AMP Synthase(7)
- TLR(127)
- Papain(1)
- PGDS(1)
- PGE synthase(26)
- SIKs(12)
- IκB/IKK(69)
- AP-1(14)
- KEAP1-Nrf2(61)
- NOD1(1)
- NF-κB(322)
- Interleukin Related(327)
- 15-lipoxygenase(2)
- Others(10)
- Aryl Hydrocarbon Receptor(43)
- CD73(17)
- Complement System(78)
- Galectin(13)
- IFNAR(64)
- NO Synthase(102)
- NOD-like Receptor (NLR)(74)
- STING(120)
- Reactive Oxygen Species(535)
- FKBP(16)
- eNOS(4)
- iNOS(29)
- nNOS(20)
- Glutathione(54)
- Adaptive Immunity(210)
- Allergy(118)
- Arthritis(34)
- Autoimmunity(181)
- Gastric Disease(94)
- Immunosuppressants(38)
- Immunotherapeutics(4)
- Innate Immunity(566)
- Pulmonary Diseases(109)
- Reactive Nitrogen Species(50)
- Specialized Pro-Resolving Mediators(49)
- Reactive Sulfur Species(28)
- BCL6(8)
- CD20(14)
- CD22(1)
- CD28(5)
- PSMA(15)
- FAP(24)
- Nuclear Factor of activated T Cells (NFAT)(2)
- Glycoprotein VI(2)
- Tim3(5)
- Hapten(1)
- Nectin-4(3)
- DOCK(4)
- MHC(12)
- Transmembrane Glycoprotein(35)
- TREM receptor(12)
- Inflammation or Immune System Disease(2)
- Musculoskeletal and Skin Disease(1)
- Fc Receptor (FcR)(13)
- IKZF Family(5)
- C-type Lectin-like Receptors (CTLRs)(9)
- Asialoglycoprotein Receptor (ASGPR)(3)
- Human leukocyte immunoglobulin (Ig)-like receptors (LILR)(1)
Products Related to Immunology/Inflammation(4756)
- GC74588PlamotamabCAS: 2138442-31-4Purity: >99.00%
Plamotamab(XmAb-13676)는 CD3와 CD20을 결합한 인간 이중특이항체(bsAb)다.
- GC74605Simlukafusp alfaCAS: 1776942-10-9Purity: >95.00%
Simlukafusp alfa (FAP-IL2v) 는 섬유질 세포 활성화 단백질 알파 (FAP α) 에 저항하는 항체와 IL-2R 베타 감마만 결합하는 IL-2 변형을 포함하는 면역 세포 인자다.
- GC74607Efineptakin alfaCAS: 2026634-47-7Purity: >99.00%
Efineptakin alfa (NT-17)은 오래 작용하는 재조합 인간 IL-7이다.
- GC74612EpcoritamabCAS: 2134641-34-0Purity: >99.00%
Epcoritamab (GEN3013)은 이등분형 IgG1 항체가 t 세포를 CD3×CD20+ 종양 세포로 전환시킨다.
- GC74614Eftozanermin alfaCAS: 1820660-69-2Purity: >95.00%
Eftozanermin alfa(ABBV-621)는 2세대 종양괴사인자 관련 사멸유도 배합체 수용체(TRAIL-R) 흥분제다.
- GC74620Zilovertamab vedotinPurity: >98.00%
Zilovertamab vedotin (VLS-101) 는 신원화 단일 클론 항체 제로타 단일 항체와 항미관 세포 독소 단일 베도틴을 포함하는 새로운 항체-약물 우연성 물질입니다.
- GC746683-Methoxy-9H-CarbazoleCAS: 18992-85-3Purity: >99.00%
3-Methoxy-9H-Carbazole 카스파스-3 활성과 세포의 활성산소 생성을 유도한다.
- GC74684Topoisomerase II inhibitor 14CAS: 305343-00-4Purity: >99.00%
Topoisomerase II inhibitor 14 (화합물 2f) 는 토폴로지아제 II의 강력한 억제제로서 항암 활성을 가지고 있다.
- GC74721Geraniol-d6 (Major)CAS: 1660976-93-1Purity: >95.00%
Geraniol-d6 (Major) 는 듀테륨 태그의 Geraniol Major입니다.
- GC74733Methoxyamine-d3 HydrochlorideCAS: 110220-55-8Purity: >99.00%
Methoxyamine-d3 Hydrochloride (O-Metldroxylamine-d3)는 Methoxyamine drochloride로 표기된 중수소이다.
- GC75705TREM2-IN-1CAS: 2000236-36-0Purity: >99.00%
TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate.
- GC78685STING-IN-15CAS: 2912492-05-6Purity: >98.00%
STING-IN-15 is a potent STING inhibitor with an IC 50 value of 116nM.
- GC78701TREM2 agonist-3Purity: >99.00%
TREM2 agonist-3 (Compound 4i) is aTREM2agonist, with aKDvalue of 19.0 ?M.
- GC78764Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAECAS: 3103526-19-5Purity: >97.50%
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
- GC78792Cys-FAP targeting peptide for FXX489 TFAPurity: >95.50%
Cys-FAP targeting peptide for FXX489 TFA is a version of the FAP-targeting peptide for FXX489 TFA that incorporates a Cys (cysteine) group.
- GC78793DOTA-GPC3 targeting peptide 2CAS: 3066439-94-6Purity: >98.50%
DOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with K d of 0.3 nM.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC74588 | Plamotamab | 2138442-31-4 | >99.00% | |
Plamotamab(XmAb-13676)는 CD3와 CD20을 결합한 인간 이중특이항체(bsAb)다. | ||||
| GC74590 | Pozelimab | 2096328-94-6 | >99.00% | |
Pozelimab (REGN3918) 는 전인IgG4 항C5 단일클론항체이다. | ||||
| GC74599 | Cobolimab | 2022215-65-0 | >98.00% | |
Cobolimab (TSR-022) 는 TIM-3 단일 클론 저항체입니다. | ||||
| GC74605 | Simlukafusp alfa | 1776942-10-9 | >95.00% | |
Simlukafusp alfa (FAP-IL2v) 는 섬유질 세포 활성화 단백질 알파 (FAP α) 에 저항하는 항체와 IL-2R 베타 감마만 결합하는 IL-2 변형을 포함하는 면역 세포 인자다. | ||||
| GC74607 | Efineptakin alfa | 2026634-47-7 | >99.00% | |
Efineptakin alfa (NT-17)은 오래 작용하는 재조합 인간 IL-7이다. | ||||
| GC74612 | Epcoritamab | 2134641-34-0 | >99.00% | |
Epcoritamab (GEN3013)은 이등분형 IgG1 항체가 t 세포를 CD3×CD20+ 종양 세포로 전환시킨다. | ||||
| GC74614 | Eftozanermin alfa | 1820660-69-2 | >95.00% | |
Eftozanermin alfa(ABBV-621)는 2세대 종양괴사인자 관련 사멸유도 배합체 수용체(TRAIL-R) 흥분제다. | ||||
| GC74620 | Zilovertamab vedotin | - | >98.00% | |
Zilovertamab vedotin (VLS-101) 는 신원화 단일 클론 항체 제로타 단일 항체와 항미관 세포 독소 단일 베도틴을 포함하는 새로운 항체-약물 우연성 물질입니다. | ||||
| GC74630 | TI17 | 1005178-02-8 | >97.00% | |
TI17 는 갑상선 호르몬 수용체 상호작용 단백질 Trip13의 억제제로서 항암 활성을 가지고 있다. | ||||
| GC74668 | 3-Methoxy-9H-Carbazole | 18992-85-3 | >99.00% | |
3-Methoxy-9H-Carbazole 카스파스-3 활성과 세포의 활성산소 생성을 유도한다. | ||||
| GC74684 | Topoisomerase II inhibitor 14 | 305343-00-4 | >99.00% | |
Topoisomerase II inhibitor 14 (화합물 2f) 는 토폴로지아제 II의 강력한 억제제로서 항암 활성을 가지고 있다. | ||||
| GC74721 | Geraniol-d6 (Major) | 1660976-93-1 | >95.00% | |
Geraniol-d6 (Major) 는 듀테륨 태그의 Geraniol Major입니다. | ||||
| GC74733 | Methoxyamine-d3 Hydrochloride | 110220-55-8 | >99.00% | |
Methoxyamine-d3 Hydrochloride (O-Metldroxylamine-d3)는 Methoxyamine drochloride로 표기된 중수소이다. | ||||
| GC75705 | TREM2-IN-1 | 2000236-36-0 | >99.00% | |
TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. | ||||
| GC75826 | YL-5092 | 3056857-07-6 | >98.00% | |
YL-5092 is a novel, highly selective inhibitor of YTHDC1 (IC 50 =7.4nM; K D =29.6nM). | ||||
| GC78685 | STING-IN-15 | 2912492-05-6 | >98.00% | |
STING-IN-15 is a potent STING inhibitor with an IC 50 value of 116nM. | ||||
| GC78701 | TREM2 agonist-3 | - | >99.00% | |
TREM2 agonist-3 (Compound 4i) is aTREM2agonist, with aKDvalue of 19.0 ?M. | ||||
| GC78764 | Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE | 3103526-19-5 | >97.50% | |
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. | ||||
| GC78787 | TRS-005 | - | >99.50% | |
TRS-005 is an anti- CD20 ADC, formed by conjugating an anti-CD20 monoclonal antibody to MMAE via a Val-Cit linker. | ||||
| GC78788 | MEDI3726 | - | >99.50% | |
MEDI3726 (ADCT-401) is a prostate-specific membrane antigen ( PSMA )-targeting antibody-drug conjugate ( ADC ), composed of LP Tesirine and antibody J591. | ||||
| GC78789 | MDX-1203 | - | >98.00% | |
MDX-1203 (BMS-936561) is an antibody-drug conjugate targeting CD70. | ||||
| GC78791 | AMG-172 | - | >98.00% | |
AMG-172 is an antibody-drug conjugate ( ADC ) composed of a fully human IgG1 monoclonal anti- CD27L antibody conjugated to DM1 via the non-cleavable linker MCC. | ||||
| GC78792 | Cys-FAP targeting peptide for FXX489 TFA | - | >95.50% | |
Cys-FAP targeting peptide for FXX489 TFA is a version of the FAP-targeting peptide for FXX489 TFA that incorporates a Cys (cysteine) group. | ||||
| GC78793 | DOTA-GPC3 targeting peptide 2 | 3066439-94-6 | >98.50% | |
DOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with K d of 0.3 nM. | ||||
